The question PGT-A is designed to answer
PGT-A stands for preimplantation genetic testing for aneuploidy. It screens cells sampled from an embryo for differences in chromosome number. An embryo with an extra or missing chromosome may have a reduced chance of developing into an ongoing pregnancy, or may be associated with a chromosome condition. The test provides information used in embryo-transfer discussions.
PGT-A does not repair an embryo or improve the underlying quality of its eggs or sperm. It also does not test for every inherited disease. PGT-M, which investigates a particular single-gene condition, is a different process with its own preparation and counselling.
How a sample becomes a result
PGT-A is performed as part of IVF. Embryos develop in culture, and suitable embryos may undergo biopsy. At the blastocyst stage, the sampled cells generally come from the outer cell layer, which contributes to placental tissues. The embryo is commonly frozen while the laboratory analyses the sample.
The genetic report describes the sampled material, not a test of every cell of the embryo. Sample quality, technical thresholds and biological variation can affect interpretation. The report and the laboratory’s reporting policy therefore matter alongside the result label.
Common result categories
| Result term | What it broadly describes | What it does not establish |
|---|---|---|
| Euploid | The tested sample has the expected chromosome number within the test’s scope. | That every cell is identical, every genetic condition is excluded or implantation will occur. |
| Aneuploid | The sample shows a chromosome-number finding classified as abnormal. | A complete explanation of all possible genetic or developmental questions. |
| Mosaic | The sample produces a pattern interpreted as a mixture of chromosome-normal and chromosome-abnormal cells. | An exact map of every cell in the embryo or a simple universal transfer recommendation. |
| Inconclusive / no result | The analysis has not provided a sufficiently clear result. | That the embryo is necessarily normal or abnormal. |
Scroll the table sideways to see all columns.
Why a mosaic or inconclusive result needs a separate discussion
A mosaic label is not one uniform finding. The chromosome involved, the pattern, laboratory thresholds and the wider embryo information may affect counselling. Some mosaic embryo transfers have resulted in healthy births, but this does not make every mosaic result equivalent or remove uncertainty.
An inconclusive result may lead to discussion of the original sample, the available embryos and whether further testing is appropriate. Re-biopsy involves additional handling and is not an automatic next step for every embryo. Decisions should reflect the actual report rather than a generic online label.
Embryo selection and the chance of a baby are different outcomes
A test may help rank embryos for transfer without increasing the total number of embryos capable of producing a live birth. A high rate per transfer can also arise because embryos classified as unsuitable are not transferred. To assess benefit, consider the chance of reaching transfer, the time involved and live-birth outcomes across the whole treatment course.
The HFEA’s patient information discusses evidence and limitations of PGT-A as a treatment add-on. Its usefulness is not the same for every patient group. Age, available embryo numbers, clinical history and the reason for proposing testing all belong in the discussion.
Testing during pregnancy remains relevant
PGT-A does not replace all prenatal screening or diagnosis. After a pregnancy is established, the obstetric or genetics team can explain the options relevant to the pregnancy and any embryo-testing history. Keep the original genetic report so that the next clinician can interpret what was tested and what remains outside its scope.
